Xanthan Gum

Xanthan gum is a high-molecular-weight polysaccharide produced by the fermentation of simple sugars by the bacterium Xanthomonas campestris. It is widely used as a thickener, stabiliser, and emulsifier in foods, pharmaceuticals, and industrial applications. Its ability to create highly viscous solutions at low concentrations and to maintain that viscosity across a wide range of temperatures and pH values makes it one of the most versatile hydrocolloids available to the food industry.

First described in the early 1950s and commercialised in the 1960s, xanthan gum is approved for use in food in most major regulatory jurisdictions worldwide. It carries the European Union designation E415 and is recognized as Generally Recognized as Safe (GRAS) by the US Food and Drug Administration. Typical use levels in food products range from 0.05% to 0.5% by weight.

For most people, xanthan gum is well tolerated at the concentrations found in food. It is not digested or absorbed in the human gut and behaves similarly to a soluble dietary fiber. Some individuals may experience mild gastrointestinal symptoms at high doses, and rare allergic reactions have been reported, particularly in those with sensitivity to the fermentation substrate (often corn, wheat, or soy). People with severe wheat allergy should check whether the product contains wheat-derived xanthan gum.

Xanthan gum has become particularly important in gluten-free cooking and baking, where it mimics the viscoelastic network that gluten provides in conventional doughs. Its inclusion on ingredient labels is straightforward in most jurisdictions, though the specific fermentation substrate is not always declared, which can be relevant for allergen-sensitive individuals.

Xanthan gum is a complex anionic heteropolysaccharide. Its primary backbone consists of repeated D-glucose units linked by β-1,4-glycosidic bonds—identical in structure to cellulose. Attached to every other glucose residue in the backbone is a trisaccharide side chain composed of two D-mannose units and one D-glucuronic acid unit. The terminal mannose residue frequently carries a pyruvate group, and the inner mannose residue commonly carries an acetate group. These charged substituents (glucuronate carboxyl groups and pyruvate ketals) give xanthan gum its anionic character and its strong affinity for water. In solution, xanthan gum adopts a stiff, rod-like double-helical conformation stabilised by non-covalent interactions between the backbone and the side chains. This ordered conformation is responsible for its pseudoplastic (shear-thinning) rheology: the gum creates high viscosity at rest but flows more easily under shear stress, recovering viscosity when shear is removed.

Xanthan gum is produced industrially by aerobic submerged fermentation. The bacterium Xanthomonas campestris (typically strain NRRL B-1459 or related strains) is inoculated into a nutrient medium containing a carbohydrate source—most commonly glucose or sucrose derived from corn starch, though wheat or soy hydrolysates are also used—along with nitrogen sources (such as ammonium salts or yeast extract), trace minerals, and pH-control agents. Fermentation runs at roughly 28–30 °C for 48–72 hours with controlled aeration and agitation. The bacterium excretes xanthan gum into the broth, which becomes increasingly viscous as polymer accumulates. After fermentation, the broth is pasteurised or heat-treated to kill the bacteria and inactivate enzymes. Xanthan gum is then recovered by precipitation with isopropanol or ethanol, which causes the polysaccharide to form fibrous strands. These are separated by filtration or centrifugation, dried (typically by drum or spray drying), milled to a fine powder, and standardized for viscosity, particle size, and purity. The finished product is tested for residual fermentation substrate, heavy metals, and microbial contamination before release.

The discovery of xanthan gum grew out of a systematic US Department of Agriculture (USDA) program in the late 1950s at the Northern Regional Research Laboratory in Peoria, Illinois, aimed at finding new commercial uses for agricultural carbohydrates. Researchers identified the polysaccharide produced by Xanthomonas campestris—a common plant pathogen responsible for 'black rot' in cruciferous vegetables—and recognized its unusual rheological properties. Key early publications appeared in the late 1950s and early 1960s. The Kelco Company (later acquired by Merck, then CP Kelco) licensed the technology and began commercial production in the United States around 1964–1969 under the trade name Keltrol®. The US FDA granted food-grade GRAS status in 1969. The European Community approved its use in food in the 1970s–1980s, eventually assigning the designation E415. Throughout the 1970s and 1980s, xanthan gum was adopted broadly in oil-field drilling fluids, cosmetics, and pharmaceuticals as well as food. The gluten-free food boom of the 2000s and 2010s dramatically expanded food-market demand, as xanthan gum became a near-universal ingredient in gluten-free bread and baked goods.

• Thickening: Creates high viscosity at very low use levels (0.05%–0.5%), reducing the need for larger quantities of starches or other hydrocolloids.
• Stabilisation: Prevents phase separation, sedimentation, and syneresis in dressings, sauces, beverages, and dairy products.
• Pseudoplastic (shear-thinning) rheology: Allows products to flow easily during pumping, filling, and pouring, yet recover thickness at rest, improving texture and mouthfeel.
• Temperature stability: Maintains viscosity across a wide temperature range, performing consistently in products subjected to pasteurisation, retorting, or freezing.
• pH stability: Functions effectively in highly acidic products (e.g., salad dressings, ketchup) and alkaline products where other gums degrade.
• Salt tolerance: Retains viscosity in high-salt and high-sugar environments where many hydrocolloids lose effectiveness.
• Freeze-thaw stability: Reduces ice crystal formation and texture degradation in frozen foods upon thawing.
• Gluten replacement: Provides the viscoelastic network needed to trap gas in gluten-free doughs, improving volume, crumb structure, and shelf life of gluten-free baked goods.
• Emulsion stabilisation: Helps keep oil and water phases combined in dressings, sauces, and beverages, reducing the need for high-speed homogenisation.
• Suspension of particulates: Keeps spices, pulp, fibers, and other insoluble particles evenly distributed throughout a product.

Established

Xanthan gum is not absorbed by the human body and passes through the gastrointestinal tract intact, functioning similarly to a soluble dietary fiber. Randomised controlled trials have shown that regular consumption of xanthan gum at doses higher than those found in typical food use (generally 15 g/day and above) can modestly reduce postprandial blood glucose and total cholesterol levels, likely by increasing the viscosity of intestinal contents and slowing glucose absorption. A 1992 crossover trial published in the American Journal of Clinical Nutrition reported reductions in total and LDL cholesterol with 15 g/day xanthan gum supplementation. These effects are consistent with the known mechanisms of soluble dietary fiber.

Possible but not firmly established

Some evidence suggests prebiotic effects: xanthan gum may selectively support growth of beneficial gut bacteria, though human clinical data are limited and the relevance of food-level doses is unclear.

Important note

The doses at which metabolic effects have been demonstrated in clinical studies are substantially higher than the milligram-level quantities consumed from typical food use. Claims that xanthan gum as a food additive provides significant health benefits to ordinary consumers are not well-supported.

Gastrointestinal effects (established at high doses)

At doses considerably above food-use levels—such as 10–15 g/day used in some clinical trials—xanthan gum can cause bloating, flatulence, loose stools, and diarrhoea. At the much lower concentrations present in food products, gastrointestinal complaints are uncommon in the general population. Individuals with irritable bowel syndrome (IBS) or other functional gut disorders may be more sensitive.

Neonatal necrotising enterocolitis (established risk at high doses in premature infants)

Several case reports and at least one case series published between 2011 and 2012 linked the use of a thickened-formula product (SimplyThick®, containing xanthan gum) to necrotising enterocolitis (NEC) in premature and medically vulnerable infants. The US FDA and Health Canada issued safety alerts in 2011–2012. The proposed mechanism involves fermentation of xanthan gum by intestinal bacteria in the immature neonatal gut, producing gas and potentially harmful by-products. This risk is specific to vulnerable premature infants; there is no evidence of NEC risk in healthy term infants or children from food-level exposures.

Allergic reactions (limited evidence)

Rare cases of allergic reactions—including urticaria, rhinitis, and anaphylaxis—have been reported, typically attributed to residual proteins from the fermentation substrate (corn, wheat, or soy) rather than to xanthan gum itself. People with diagnosed severe allergies to corn, wheat, or soy should seek information on the specific substrate used in the xanthan gum product they are consuming. Xanthan gum produced on wheat substrate may theoretically contain residual gluten proteins, although commercially available food-grade xanthan gum typically tests below 20 ppm gluten in studies reviewed by coeliac disease organizations.

Occupational asthma (limited evidence)

Inhalation of xanthan gum dust in occupational settings has been associated in a small number of case reports with rhinitis and asthma-like symptoms. This is an occupational, not dietary, concern.

Interactions with medications (ongoing research)

Because xanthan gum slows gastric emptying and increases intestinal viscosity, there is a theoretical concern that it could delay absorption of oral medications. Clinically significant interactions have not been systematically documented, but individuals taking time-sensitive medications should be aware of this possibility.

No numerical Acceptable Daily Intake (ADI) has been assigned by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), which concluded that the available data did not necessitate specifying a numerical ADI—a designation of 'ADI not specified' (or 'not limited') indicating the substance is of low toxicological concern at food-use levels. The European Food Safety Authority (EFSA) has similarly not set a numerical ADI, evaluating the compound as safe under current conditions of use.

For healthy adults and children, the amounts consumed through normal dietary exposure pose no established safety concern. Estimated dietary exposure in the EU has been assessed by EFSA as well below levels associated with any adverse effects.

For premature or medically vulnerable infants, xanthan-gum-based thickeners should be avoided unless specifically directed by a healthcare professional, given the association with necrotising enterocolitis documented in case reports. The FDA and Health Canada have issued specific warnings in this regard.

For pregnant and breastfeeding women, no specific restriction exists; current regulatory assessments find no reason for concern at food-use levels. Supplements delivering gram-level doses have not been adequately studied in pregnancy and their use should be discussed with a clinician.

The peer-reviewed literature on xanthan gum is extensive, spanning food science, nutrition, and medicine. The most cited nutritional studies are human crossover trials from the 1980s and 1990s (notably Vorster et al., 1992, American Journal of Clinical Nutrition) demonstrating reductions in serum cholesterol and postprandial glucose at supplemental doses of 15 g/day—doses far above food-use levels. These studies have good internal validity but limited generalisability to the small amounts found in food products. A 2017 EFSA re-evaluation systematically reviewed the toxicological database, including multiple 90-day and chronic rodent feeding studies, reproduction and developmental toxicity studies, and genotoxicity assessments; no adverse effects were identified at doses up to the highest tested levels, supporting the 'ADI not specified' designation. The necrotising enterocolitis signal in premature infants is based primarily on case reports and a retrospective case series (Beal et al., 2012, Journal of Pediatrics); prospective randomised evidence is unavailable for ethical reasons. Research into the prebiotic potential of xanthan gum is emerging but remains in early stages, with most data from in vitro fermentation or animal models rather than controlled human trials. The rheological and functional food-science literature on xanthan gum is very robust, with hundreds of peer-reviewed papers characterising its behavior under varying conditions of temperature, pH, salt, and shear. Overall, the evidence base for safety in normal food use is strong, while evidence for nutritional benefit at food-use doses is weak.

Xanthan gum has attracted recurring public concern, primarily driven by its bacterial origin and its use as an additive in processed and ultra-processed foods. Some natural-health and 'clean label' advocates portray it as a foreign chemical or a harmful industrial by-product, claims that are not supported by the regulatory or scientific record. A significant source of confusion is the 2011–2012 infant formula safety alert: media coverage sometimes generalised the risk to all consumers, when the documented concern is specifically limited to premature and medically vulnerable infants receiving xanthan-gum-based thickeners. The ingredient has also been questioned in the context of the gluten-free market, with some commentators suggesting it may contribute to bloating in people with coeliac disease or non-coeliac gluten sensitivity; clinical data to support this at typical food-use levels are lacking, though individual sensitivities at higher intakes are plausible. Concerns about allergenicity have been amplified on social media, particularly among people with wheat allergies; while the issue of fermentation substrate is legitimate and worth checking with manufacturers, commercially produced food-grade xanthan gum typically meets accepted gluten thresholds. The ingredient is sometimes mischaracterised as genetically modified; while the producing bacterium is naturally occurring, some manufacturers do use genetically modified fermentation strains, but the xanthan gum polymer itself is chemically identical regardless of strain type. Overall, mainstream scientific and regulatory opinion holds that xanthan gum is safe for the general population at food-use levels.

The fermentation-based production of xanthan gum requires significant quantities of carbohydrate feedstocks (typically corn or wheat), water, nitrogen nutrients, and energy for aeration, heating, and downstream processing. The fermentation broth generates wastewater with high biological oxygen demand (BOD), which must be treated before discharge. The use of isopropanol or ethanol as precipitation solvents requires careful management and recovery to minimize solvent emissions. Life cycle assessments of xanthan gum production are limited in the published literature, but general analyses of microbial polysaccharide fermentation suggest a moderate-to-high carbon footprint relative to plant-derived hydrocolloids, depending heavily on the energy source used at the production facility and the efficiency of solvent recovery. On the positive side, xanthan gum is biodegradable and does not persist in the environment. Ongoing research in the industrial fermentation sector aims to reduce substrate costs and improve energy efficiency, including interest in using lignocellulosic waste streams as fermentation feedstocks. The environmental footprint of xanthan gum used in food is difficult to assess in isolation given the very small use levels (fractions of a percent) in most products.

Workers involved in the milling, packaging, or handling of dry xanthan gum powder may be exposed to airborne dust. A small number of occupational case reports describe rhinitis, conjunctivitis, and asthma-like symptoms in workers with heavy, prolonged dust exposure, consistent with occupational hypersensitivity to a high-molecular-weight biological material. Standard industrial hygiene measures—including dust extraction, enclosed handling systems, and respiratory protective equipment where dust levels are elevated—are recommended in manufacturing facilities. There is no established systemic toxicity risk from occupational skin or inhalation exposure at levels achievable with appropriate engineering controls. Dermal sensitisation is not well-documented. Workers with pre-existing respiratory conditions or known allergies to the fermentation substrates used should be managed with occupational health oversight.

Xanthan gum has been tested in numerous animal toxicology studies, including acute oral toxicity, subchronic (90-day), chronic, and multigenerational reproduction studies in rats, mice, and dogs. JECFA and EFSA reviewed these studies extensively. In all chronic rodent feeding studies, xanthan gum did not cause treatment-related adverse effects at the highest doses tested (up to several grams per kilogram body weight per day), which were many orders of magnitude above human dietary exposure. No carcinogenicity, genotoxicity, teratogenicity, or reproductive toxicity was demonstrated. Some animal studies showed dose-dependent increases in caecum size and changes in gut microbiota composition, consistent with the fermentable fiber properties of the compound rather than toxic mechanisms. Studies in dogs showed similar tolerance. The animal evidence base for safety is considered strong and has been a key pillar of the regulatory approvals globally.

Human clinical studies on xanthan gum have largely focused on its physiological effects as a dietary fiber supplement rather than on its safety as a food additive. Controlled trials from the 1980s and 1990s administered 15 g/day as a supplement to healthy volunteers and diabetic patients, finding modest reductions in total cholesterol, LDL cholesterol, and postprandial blood glucose. These effects are well-characterised but only occur at doses substantially higher than ordinary dietary exposure. Gastrointestinal tolerability at food-use levels is supported by decades of widespread use without population-level safety signals, as well as by short-term volunteer studies at moderate doses. The most clinically significant human safety signal—the association of xanthan-gum-based thickeners with necrotising enterocolitis—arises from case series and retrospective analyses in neonatal intensive care settings, not from the general population. No prospective interventional data exist in premature infants for ethical reasons. Studies examining xanthan gum's effects on gut microbiota composition in adults are emerging but remain limited; one small clinical study published in 2021 in Microbiome identified xanthan gum as a substrate selectively metabolised by specific gut bacteria, raising questions about whether individual differences in microbiome composition might influence both tolerability and any functional effects.

In the European Union, xanthan gum must be declared on food ingredient lists by its functional class name followed by its specific name or E number: for example, 'thickener: xanthan gum' or 'stabiliser (E415)'. In the United States, it must be listed by its common or usual name, 'xanthan gum', in the ingredient list in descending order of weight. In Australia and New Zealand, it may appear as 'thickener (415)' or by name. In Canada, it is declared by name in the ingredient list. The fermentation substrate (corn, wheat, soy) is generally not required to be declared as part of the xanthan gum declaration, although some manufacturers voluntarily indicate this on their labeling or on their websites. Individuals with severe allergies to these substrates may need to contact the manufacturer directly. Xanthan gum may also be listed under trade names such as Keltrol® or Xantural® in industrial-use specifications, but these names do not appear on consumer food labels.

Xanthan gum itself is not present as a naturally occurring component of any common food. It is produced exclusively by the bacterium Xanthomonas campestris under fermentation conditions and does not occur at significant levels in plant or animal foods. However, other naturally occurring polysaccharides with broadly similar thickening and gelling properties are found in foods: guar gum (from guar beans), locust bean gum (from carob seeds), agar (from red algae), pectin (from fruit cell walls), and beta-glucan (from oats and barley) all provide viscosity and some stabilising effects through related but distinct molecular mechanisms. Mucilaginous seeds such as chia and flaxseed release polysaccharide gels on hydration that are sometimes used as functional alternatives to xanthan gum in home cooking.